Your account is not claimed yet. You can sign up with ORCID to claim your account.

Andras Inotai (András Inotai)

Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 6

Top Venues

Cost effectiveness and resource allocation : C/E

BioMed research international

BMC health services research

Expert review of pharmacoeconomics & outcomes research

ELTE Társadalomtudományi Kar

Semmelweis Egyetem Doktori Iskola (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

ELTE Társadalomtudományi Kar Sep 15o 2016

Hungary

Assistant professor :: Department of Health Policy and Health Economics, Institute Economics

Education History

Semmelweis Egyetem Doktori Iskola

Hungary

PHD

Publications

Brian Godman, Magdalene Wladysiuk, Stuart McTaggart, Amanj Kurdi, Eleonora Allocati, Mihajlo Michael Jakovljevic, Francis Kalemeera, Iris Hoxha, Anna Nachtnebel, Robert Sauermann, Manfred Hinteregger, Vanda Marković-Peković, Biljana Tubic, Guenka Petrova, Konstantin Tachkov, Juraj Slabý, Radka Nejezchlebova, Iva Selke Krulichová, Ott Laius, Gisbert Selke, Irene Langner, András Harsanyi, Andras Inotai, Arianit Jakupi, Svens Henkuzens, Kristina Garuolienė, Jolanta Gulbinovič, Patricia Vella Bonanno, Jakub Rutkowski, Skule Ingeberg, Øyvind Melien, Ileana Mardare, Jurij Fürst, Sean MacBride-Stewart, Carol Holmes, Caridad Pontes, Corinne Zara, Marta Turu Pedrola, Mikael Hoffmann, Vasileios Kourafalos, Alice Pisana, Rita Banzi, Stephen M Campbell, Bjorn Wettermark
Corrigendum to "Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications". BioMed research international 2023 (2023)
Zsuzsanna Ida Petykó, Zoltán Kaló, Jaime Espin, Kateřina Podrazilová, Tomáš Tesař, Nikos Maniadakis, Frank-Ulrich Fricke, Andras Inotai
Development of a core evaluation framework of value-added medicines: report 1 on methodology and findings. Cost effectiveness and resource allocation : C/E 19 (1) (2021)
Zoltán Kaló, Zsuzsanna Ida Petykó, Frank-Ulrich Fricke, Nikos Maniadakis, Tomáš Tesař, Kateřina Podrazilová, Jaime Espin, Andras Inotai
Development of a core evaluation framework of value-added medicines: report 2 on pharmaceutical policy perspectives. Cost effectiveness and resource allocation : C/E 19 (1) (2021)
Zsuzsanna Ida Petykó, Andras Inotai, Anke-Peggy Holtorf, Diana Brixner, Zoltán Kaló
Barriers and facilitators of exploiting the potential of value-added medicines. Expert review of pharmacoeconomics & outcomes research 20 (3) (2020)
Andras Inotai, Diana Brixner, Nikos Maniadakis, Iwan Dwiprahasto, Erna Kristin, Agus Prabowo, Alfi Yasmina, Sigit Priohutomo, Bertalan Németh, Kalman Wijaya, Zoltan Kalo
Development of multi-criteria decision analysis (MCDA) framework for off-patent pharmaceuticals - an application on improving tender decision making in Indonesia. BMC health services research 18 (1) (2018)
Andras Inotai, Marcell Csanadi, Guenka Petrova, Maria Dimitrova, Tomasz Bochenek, Tomas Tesar, Kristina York, Leos Fuksa, Alexander Kostyuk, Laszlo Lorenzovici, Vitaly Omelyanovskiy, Katalin Egyed, Zoltan Kalo
Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts. BioMed research international 2018 (2018)

Andras Inotai.css-eqlu8i{font-size:small;padding-left:4px;} (András Inotai)

Publication Activity (10 Years)

Top Topics

Top Venues

Andras Inotai (András Inotai)